Press Releases

Thursday, 25 April 2019

Documents concerning new issue of shares

The documents below can now be find on our website

Full terms and conditions for the issuance of shares

The Board's opinion on significant events and set-off

Auditor's opinion on significant events and set-off

The documents are all in Swedish

 

For more information, contact

Berit Lindholm, CEO Bluefish Pharmaceuticals 

Tel. 46 8 519 116 00

Email: berit.lindholm@bluefishpharma.com

 

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of approximately 80 products and is growing.

www.bluefishpharma.com

Contact us

Bluefish Pharmaceuticals AB
Gävlegatan 22
SE-113 30 Stockholm, Sweden
Tel: +46 8 5191 1600
Fax: +46 8 5191 1690
info-se@bluefishpharma.com

Important Contacts

For Business Development

business.development@bluefishpharma.com

Customer Service or Reporting Adverse Events

drugreaction@bluefishpharma.com

Complaints

Tel +46 8 5191 1600
Fax +46 8 5191 1690
E-mail complaints@bluefishpharma.com

Stay updated on our latest news

Subscribe